Long non-coding RNA MALAT1 expression in patients with gestational diabetes mellitus.
To monitor the expression of long non-coding RNAs (lncRNAs) and changes in metabolic profiles among patients with gestational diabetes mellitus (GDM). A retrospective case-control study was conducted using data for women treated at a hospital in China between October 8, 2014, and April 15, 2015. Patients diagnosed with GDM using an oral glucose tolerance test at 24-28 weeks of pregnancy (n=50) were included. The control group comprised pregnant women without GDM (n=47). Serum levels of lncRNA MALAT1, lncRNA p21, and lncRNA H19 were assessed using the reverse transcription polymerase chain reaction. Plasma glucose and lipid levels were assessed biochemically. The expression level of lncRNA MALAT1 was higher among the cases than the controls (P=0.007). Expression of IncRNA MALAT1 among the patients with GDM correlated with both lncRNA p21 (r=0.333, P=0.018) and lncRNA H19 (r=0.314, P=0.030). Levels of triglycerides and total cholesterol differed between the control group and patients with GDM (3.6 ± 2.6 mmol/L vs 3.8 ± 1.5 mmol/L and 6.54 ± 1.30 mmol/L vs 7.40 ± 0.90 mmol/L, respectively; P<0.05). The area under the receiver operating characteristic curve was 0.654 (95% confidence interval 0.543-0.768, P<0.001). Expression of lncRNA MALAT1 could offer a novel biomarker to predict GDM.